Cover Image
市場調查報告書

治療癌症的單株抗體相關各種合作契約:契約條件·協定內容

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 238158
出版日期 內容資訊 英文 303 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
治療癌症的單株抗體相關各種合作契約:契約條件·協定內容 Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials
出版日期: 2016年09月01日 內容資訊: 英文 303 Pages
簡介

本報告提供治療癌症的單株抗體相關各種合作相關契約調查分析,提供近幾年的各種契約趨勢,大規模契約及大醫藥品經營者的契約概要,各契約區分·開發階段·抗體類型·適應症種類的名錄等彙整資料,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 治療癌症的單株抗體相關各種契約動向

  • 簡介
  • 過去數年的治療癌症的單株抗體相關合作
  • 大製藥公司治療癌症的單株抗體相關契約活動
  • 大生物科技企業治療癌症的單株抗體相關契約活動
  • 治療癌症的單株抗體合作最活躍的企業
  • 治療癌症的單株抗體相關合作:各類型契約
  • 治療癌症的單株抗體相關合作:各開發階段
  • 治療癌症的單株抗體相關合作:各適應症(癌症)
  • 治療癌症的單株抗體相關合作:各抗體類型
  • 公開的治療癌症單株抗體相關合作的契約條件

第3章 主要契約

  • 簡介
  • 主要契約:各交易金額

第4章 大型製藥公司針對癌症治療單株抗體契約動向

  • 簡介
  • 大型製藥公司契約的利用法
  • 大型製藥公司針對癌症治療單株抗體合作企業簡介

第5章 大生物科技企業針對癌症治療單株抗體契約動向

  • 簡介
  • 大生物科技企業的契約的利用法
  • 大生物科技企業針對癌症治療單株抗體合作企業簡介

第6章 癌症治療用單株抗體的契約名錄

  • 簡介
  • 企業A-Z
  • 各開發階段
    • 藥物研發
    • 製劑
    • 上市
    • 階段Ⅰ
    • 階段Ⅱ
    • 階段Ⅲ
    • 前臨床
    • 法規
  • 各類型契約
    • 資產購買
    • 轉讓
    • 大型對外授權
    • 共同開發
    • 共同R&D
    • 服務契約
    • 共同促銷
    • 受託服務
    • CRADA
    • 交叉授權
    • 開發
    • 流通銷售
    • 股票購買
    • 評估
    • 轉讓
    • 合資企業
    • 授權
    • 貸款
    • 製造
    • 行銷
    • 材料轉移
    • 選擇
    • 推銷
    • 研究
    • 和解相關
    • 消耗
    • 輔助許可證
    • 供給
    • 技術轉移
    • 契約解除
  • 各適應症(癌症)
  • 各抗體類型

第7章 合作機會

  • 網路夥伴合作
  • 合作夥伴活動
  • 相關資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP22012

The ‘Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players, financials and forecasts’ report provides comprehensive understanding and unprecedented access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies

The ‘Global Cancer Monoclonal Antibody Partnering 2010-2016: Deal trends, players, financials and forecasts’ report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in cancer monoclonal antibody partnering deals
  • Most active companies in cancer monoclonal antibody partnering
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer monoclonal antibody partnering contract documents
  • Top cancer monoclonal antibody deals by value

This report provides details of the latest Cancer monoclonal antibody agreements announced in the healthcare sectors.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb
  • Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all Cancer monoclonal antibody partnering deals announced since Jan 2010, including financial terms where available, including links to online deal records of actual Cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer monoclonal antibody dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer monoclonal antibody deals since 2010. Deals are listed by headline value, signed by big pharma, most active Cancer monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of Cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2010. The chapter is organized by specific Cancer monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Cancer monoclonal antibody partnering company A-Z, deal type definitions and Cancer monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer monoclonal antibody partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer monoclonal antibody technologies and products.

Key benefits

‘Global Cancer Monoclonal Antibody Partnering Terms & Agreements’ provides the reader with the following key benefits:

  • In-depth understanding of cancer monoclonal antibody deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Access to the structure of cancer monoclonal antibody agreements with numerous real life case studies
  • Comprehensive access to over 360 actual cancer monoclonal antibody deals entered into by the world's biopharma companies
  • Identify most active companies in cancer monoclonal antibody partnering
  • Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
  • Spot the emerging companies in the cancer monoclonal antibody area

Report scope

‘Global Cancer Monoclonal Antibody Partnering Terms & Agreements’ is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.

‘Cancer Monoclonal Antibody Partnering Terms & Agreements’ includes:

  • Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2010
  • Analysis of cancer monoclonal antibody deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 360 cancer monoclonal antibody deal records
  • The leading cancer monoclonal antibody deals by value since 2010

In ‘Cancer Monoclonal Antibody Partnering Terms & Agreements’, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target
  • Monoclonal antibody type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Cancer Monoclonal Antibody Partnering Terms & Agreements’ report provides comprehensive access to available deals and contract documents for over 360 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts’ provides the reader with the following key benefits:

  • In-depth understanding of cancer monoclonal antibody deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Access to the structure of cancer monoclonal antibody agreements with numerous real life case studies
  • Comprehensive access to over 360 actual cancer monoclonal antibody deals entered into by the world's biopharma companies
  • Identify the most active companies engaged in cancer monoclonal antibody partnering
  • Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer monoclonal antibody dealmaking

  • 2.1. Introduction
  • 2.2. Cancer monoclonal antibody partnering over the years
  • 2.3. Most active Cancer monoclonal antibody dealmakers
  • 2.4. Cancer monoclonal antibody partnering by deal type
  • 2.5. Cancer monoclonal antibody partnering by therapy area
  • 2.6. Deal terms for Cancer monoclonal antibody partnering
    • 2.6.1 Cancer monoclonal antibody partnering headline values
    • 2.6.2 Cancer monoclonal antibody deal upfront payments
    • 2.6.3 Cancer monoclonal antibody deal milestone payments
    • 2.6.4 Cancer monoclonal antibody royalty rates

Chapter 3 - Leading Cancer monoclonal antibody deals

  • 3.1. Introduction
  • 3.2. Top Cancer monoclonal antibody deals by value

Chapter 4 - Most active Cancer monoclonal antibody dealmakers

  • 4.1. Introduction
  • 4.2. Most active Cancer monoclonal antibody dealmakers
  • 4.3. Most active Cancer monoclonal antibody partnering company profiles

Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Cancer monoclonal antibody contracts dealmaking directory

Chapter 6 - Cancer monoclonal antibody dealmaking by technology type

  • Monoclonal antibodies
  • Chimeric mAb
  • Humanized mAb
  • Human mAb
  • Murine mAb

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Cancer monoclonal antibody deals by company A-Z
  • Appendix 2 - Cancer monoclonal antibody deals by stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation
  • Appendix 3 - Cancer monoclonal antibody deals by deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Appendix 4 - Cancer monoclonal antibody deals by therapy area
  • Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Therapeutic antibody definitions
  • Figure 2: Cancer monoclonal antibody partnering since 2010
  • Figure 3: Active Cancer monoclonal antibody dealmaking activity- 2010 to 2016
  • Figure 4: Cancer monoclonal antibody partnering by deal type since 2010
  • Figure 5: Cancer monoclonal antibody partnering by disease type since 2010
  • Figure 6: Cancer monoclonal antibody deals with a headline value
  • Figure 7: Cancer monoclonal antibody deals with an upfront value
  • Figure 8: Cancer monoclonal antibody deals with a milestone value
  • Figure 9: Cancer monoclonal antibody deals with a royalty rate value
  • Figure 10: Top Cancer monoclonal antibody deals by value since 2010
  • Figure 11: Most active Cancer monoclonal antibody dealmakers 2010 to 2016
  • Figure 12: Online partnering resources
  • Figure 13: Forthcoming partnering events
Back to Top